Prostate cancer prevention: concepts and clinical recommendations
Prevention is an important strategy for limiting prostate cancer morbidity and mortality. Two major types of prevention are primary (reduction of incident cases) and tertiary (inhibition of disease progression and recurrence). Pharmacological and dietary interventions have potential functions in bot...
Gespeichert in:
| Veröffentlicht in: | Prostate cancer and prostatic diseases 2010-12, Vol.13 (4), p.300-306 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 306 |
|---|---|
| container_issue | 4 |
| container_start_page | 300 |
| container_title | Prostate cancer and prostatic diseases |
| container_volume | 13 |
| creator | Silberstein, J L Parsons, J K |
| description | Prevention is an important strategy for limiting prostate cancer morbidity and mortality. Two major types of prevention are primary (reduction of incident cases) and tertiary (inhibition of disease progression and recurrence). Pharmacological and dietary interventions have potential functions in both the primary and tertiary prevention of prostate cancer. Five-α reductase inhibitors (5-ARIs) reduce the incidence of prostate cancer in both general and higher-risk populations and are currently under study for tertiary prevention in active surveillance and biochemical recurrence patients. Selenium, vitamin E, and vitamin C do not prevent incident prostate cancer in the general population; however, other promising diet-based interventions are currently under study for tertiary prevention. We recommend consideration of 5-ARIs for prostate cancer prevention in (1) asymptomatic men with a PSA ⩽3.0 ng ml
–1
who are undergoing or anticipate undergoing PSA screening for early detection of prostate cancer and (2) asymptomatic men with PSA ⩾2.5 and ⩽10 ng ml
–1
and an earlier prostate biopsy negative for cancer. Men should be informed of the potential risks of 5-ARI therapy. Currently, there is neither clinical evidence to support the use of 5-ARIs for tertiary prevention in active surveillance or biochemical recurrence populations, nor micronutrients for prostate cancer prevention of any type. |
| doi_str_mv | 10.1038/pcan.2010.18 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_764495811</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A242373977</galeid><sourcerecordid>A242373977</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-e4bd6fd368c088518061855c620d3ebacfb849bd006abd5fb39cf1f9c0c60f6a3</originalsourceid><addsrcrecordid>eNp10d1vlTAYBvDGaNyc3nltiCZ6I8e39IPi3cniV7JEL_S6KeXtxgIttsXE_97imZszLlxAy68PtA8hTynsKDD1ZrHG7xrYhuoeOaa8lbWQoO6XZyZF3SrRHJFHKV0CQEc7eEiOGhCybUR7TPZfYkjZZKxKjMVYLRF_oM9j8G8rG8rUklNl_FDZafSjNVMV0YZ5Rj-YTaXH5IEzU8InV_cT8u39u6-nH-uzzx8-ne7PaitA5hp5P0g3MKksKCWoAkmVEFY2MDDsjXW94l0_AEjTD8L1rLOOus6CleCkYSfk1SF3ieH7iinreUwWp8l4DGvSreS8E4rSIp__Iy_DGn35uYIY40LwtqAXd6FGcsGoZB3cqHMzoR69Czkau31Y7xvesJZ17Za1-48q14DzWA4R3Vjmby14-deCCzRTvkhhWn8f6G34-gBtqSlFdHqJ42ziT01Bb_XrrX691a-pKvzZ1abWfsbhGv_pu4D6AFJ55c8x3uz6jsDq4L3Ja8TrwA1tppBfS2bCOw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2645316390</pqid></control><display><type>article</type><title>Prostate cancer prevention: concepts and clinical recommendations</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Silberstein, J L ; Parsons, J K</creator><creatorcontrib>Silberstein, J L ; Parsons, J K</creatorcontrib><description>Prevention is an important strategy for limiting prostate cancer morbidity and mortality. Two major types of prevention are primary (reduction of incident cases) and tertiary (inhibition of disease progression and recurrence). Pharmacological and dietary interventions have potential functions in both the primary and tertiary prevention of prostate cancer. Five-α reductase inhibitors (5-ARIs) reduce the incidence of prostate cancer in both general and higher-risk populations and are currently under study for tertiary prevention in active surveillance and biochemical recurrence patients. Selenium, vitamin E, and vitamin C do not prevent incident prostate cancer in the general population; however, other promising diet-based interventions are currently under study for tertiary prevention. We recommend consideration of 5-ARIs for prostate cancer prevention in (1) asymptomatic men with a PSA ⩽3.0 ng ml
–1
who are undergoing or anticipate undergoing PSA screening for early detection of prostate cancer and (2) asymptomatic men with PSA ⩾2.5 and ⩽10 ng ml
–1
and an earlier prostate biopsy negative for cancer. Men should be informed of the potential risks of 5-ARI therapy. Currently, there is neither clinical evidence to support the use of 5-ARIs for tertiary prevention in active surveillance or biochemical recurrence populations, nor micronutrients for prostate cancer prevention of any type.</description><identifier>ISSN: 1365-7852</identifier><identifier>EISSN: 1476-5608</identifier><identifier>DOI: 10.1038/pcan.2010.18</identifier><identifier>PMID: 20567257</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/67/2195 ; 692/699/67/589/466 ; 692/700/565/1436/1983 ; Algorithms ; Ascorbic acid ; Asymptomatic ; Biomedical and Life Sciences ; Biomedicine ; Biopsy ; Cancer Research ; Carcinoma - prevention & control ; Care and treatment ; Chemoprevention - methods ; Concept Formation ; Development and progression ; Diagnosis ; Disease prevention ; Health aspects ; Health Planning Guidelines ; Humans ; Male ; Micronutrients ; Morbidity ; Populations ; Prevention ; Primary Prevention - methods ; Prostate cancer ; Prostatic Neoplasms - prevention & control ; Reductases ; review ; Selenium ; Surveillance ; Tertiary Prevention - methods ; Vitamin E</subject><ispartof>Prostate cancer and prostatic diseases, 2010-12, Vol.13 (4), p.300-306</ispartof><rights>Macmillan Publishers Limited 2010</rights><rights>COPYRIGHT 2010 Nature Publishing Group</rights><rights>Macmillan Publishers Limited 2010.</rights><rights>Copyright Nature Publishing Group Dec 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-e4bd6fd368c088518061855c620d3ebacfb849bd006abd5fb39cf1f9c0c60f6a3</citedby><cites>FETCH-LOGICAL-c506t-e4bd6fd368c088518061855c620d3ebacfb849bd006abd5fb39cf1f9c0c60f6a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20567257$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Silberstein, J L</creatorcontrib><creatorcontrib>Parsons, J K</creatorcontrib><title>Prostate cancer prevention: concepts and clinical recommendations</title><title>Prostate cancer and prostatic diseases</title><addtitle>Prostate Cancer Prostatic Dis</addtitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><description>Prevention is an important strategy for limiting prostate cancer morbidity and mortality. Two major types of prevention are primary (reduction of incident cases) and tertiary (inhibition of disease progression and recurrence). Pharmacological and dietary interventions have potential functions in both the primary and tertiary prevention of prostate cancer. Five-α reductase inhibitors (5-ARIs) reduce the incidence of prostate cancer in both general and higher-risk populations and are currently under study for tertiary prevention in active surveillance and biochemical recurrence patients. Selenium, vitamin E, and vitamin C do not prevent incident prostate cancer in the general population; however, other promising diet-based interventions are currently under study for tertiary prevention. We recommend consideration of 5-ARIs for prostate cancer prevention in (1) asymptomatic men with a PSA ⩽3.0 ng ml
–1
who are undergoing or anticipate undergoing PSA screening for early detection of prostate cancer and (2) asymptomatic men with PSA ⩾2.5 and ⩽10 ng ml
–1
and an earlier prostate biopsy negative for cancer. Men should be informed of the potential risks of 5-ARI therapy. Currently, there is neither clinical evidence to support the use of 5-ARIs for tertiary prevention in active surveillance or biochemical recurrence populations, nor micronutrients for prostate cancer prevention of any type.</description><subject>692/699/67/2195</subject><subject>692/699/67/589/466</subject><subject>692/700/565/1436/1983</subject><subject>Algorithms</subject><subject>Ascorbic acid</subject><subject>Asymptomatic</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biopsy</subject><subject>Cancer Research</subject><subject>Carcinoma - prevention & control</subject><subject>Care and treatment</subject><subject>Chemoprevention - methods</subject><subject>Concept Formation</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Disease prevention</subject><subject>Health aspects</subject><subject>Health Planning Guidelines</subject><subject>Humans</subject><subject>Male</subject><subject>Micronutrients</subject><subject>Morbidity</subject><subject>Populations</subject><subject>Prevention</subject><subject>Primary Prevention - methods</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - prevention & control</subject><subject>Reductases</subject><subject>review</subject><subject>Selenium</subject><subject>Surveillance</subject><subject>Tertiary Prevention - methods</subject><subject>Vitamin E</subject><issn>1365-7852</issn><issn>1476-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp10d1vlTAYBvDGaNyc3nltiCZ6I8e39IPi3cniV7JEL_S6KeXtxgIttsXE_97imZszLlxAy68PtA8hTynsKDD1ZrHG7xrYhuoeOaa8lbWQoO6XZyZF3SrRHJFHKV0CQEc7eEiOGhCybUR7TPZfYkjZZKxKjMVYLRF_oM9j8G8rG8rUklNl_FDZafSjNVMV0YZ5Rj-YTaXH5IEzU8InV_cT8u39u6-nH-uzzx8-ne7PaitA5hp5P0g3MKksKCWoAkmVEFY2MDDsjXW94l0_AEjTD8L1rLOOus6CleCkYSfk1SF3ieH7iinreUwWp8l4DGvSreS8E4rSIp__Iy_DGn35uYIY40LwtqAXd6FGcsGoZB3cqHMzoR69Czkau31Y7xvesJZ17Za1-48q14DzWA4R3Vjmby14-deCCzRTvkhhWn8f6G34-gBtqSlFdHqJ42ziT01Bb_XrrX691a-pKvzZ1abWfsbhGv_pu4D6AFJ55c8x3uz6jsDq4L3Ja8TrwA1tppBfS2bCOw</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Silberstein, J L</creator><creator>Parsons, J K</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20101201</creationdate><title>Prostate cancer prevention: concepts and clinical recommendations</title><author>Silberstein, J L ; Parsons, J K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-e4bd6fd368c088518061855c620d3ebacfb849bd006abd5fb39cf1f9c0c60f6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>692/699/67/2195</topic><topic>692/699/67/589/466</topic><topic>692/700/565/1436/1983</topic><topic>Algorithms</topic><topic>Ascorbic acid</topic><topic>Asymptomatic</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biopsy</topic><topic>Cancer Research</topic><topic>Carcinoma - prevention & control</topic><topic>Care and treatment</topic><topic>Chemoprevention - methods</topic><topic>Concept Formation</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Disease prevention</topic><topic>Health aspects</topic><topic>Health Planning Guidelines</topic><topic>Humans</topic><topic>Male</topic><topic>Micronutrients</topic><topic>Morbidity</topic><topic>Populations</topic><topic>Prevention</topic><topic>Primary Prevention - methods</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - prevention & control</topic><topic>Reductases</topic><topic>review</topic><topic>Selenium</topic><topic>Surveillance</topic><topic>Tertiary Prevention - methods</topic><topic>Vitamin E</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Silberstein, J L</creatorcontrib><creatorcontrib>Parsons, J K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Prostate cancer and prostatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Silberstein, J L</au><au>Parsons, J K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prostate cancer prevention: concepts and clinical recommendations</atitle><jtitle>Prostate cancer and prostatic diseases</jtitle><stitle>Prostate Cancer Prostatic Dis</stitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>13</volume><issue>4</issue><spage>300</spage><epage>306</epage><pages>300-306</pages><issn>1365-7852</issn><eissn>1476-5608</eissn><abstract>Prevention is an important strategy for limiting prostate cancer morbidity and mortality. Two major types of prevention are primary (reduction of incident cases) and tertiary (inhibition of disease progression and recurrence). Pharmacological and dietary interventions have potential functions in both the primary and tertiary prevention of prostate cancer. Five-α reductase inhibitors (5-ARIs) reduce the incidence of prostate cancer in both general and higher-risk populations and are currently under study for tertiary prevention in active surveillance and biochemical recurrence patients. Selenium, vitamin E, and vitamin C do not prevent incident prostate cancer in the general population; however, other promising diet-based interventions are currently under study for tertiary prevention. We recommend consideration of 5-ARIs for prostate cancer prevention in (1) asymptomatic men with a PSA ⩽3.0 ng ml
–1
who are undergoing or anticipate undergoing PSA screening for early detection of prostate cancer and (2) asymptomatic men with PSA ⩾2.5 and ⩽10 ng ml
–1
and an earlier prostate biopsy negative for cancer. Men should be informed of the potential risks of 5-ARI therapy. Currently, there is neither clinical evidence to support the use of 5-ARIs for tertiary prevention in active surveillance or biochemical recurrence populations, nor micronutrients for prostate cancer prevention of any type.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>20567257</pmid><doi>10.1038/pcan.2010.18</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-7852 |
| ispartof | Prostate cancer and prostatic diseases, 2010-12, Vol.13 (4), p.300-306 |
| issn | 1365-7852 1476-5608 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_764495811 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | 692/699/67/2195 692/699/67/589/466 692/700/565/1436/1983 Algorithms Ascorbic acid Asymptomatic Biomedical and Life Sciences Biomedicine Biopsy Cancer Research Carcinoma - prevention & control Care and treatment Chemoprevention - methods Concept Formation Development and progression Diagnosis Disease prevention Health aspects Health Planning Guidelines Humans Male Micronutrients Morbidity Populations Prevention Primary Prevention - methods Prostate cancer Prostatic Neoplasms - prevention & control Reductases review Selenium Surveillance Tertiary Prevention - methods Vitamin E |
| title | Prostate cancer prevention: concepts and clinical recommendations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T00%3A24%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prostate%20cancer%20prevention:%20concepts%20and%20clinical%20recommendations&rft.jtitle=Prostate%20cancer%20and%20prostatic%20diseases&rft.au=Silberstein,%20J%20L&rft.date=2010-12-01&rft.volume=13&rft.issue=4&rft.spage=300&rft.epage=306&rft.pages=300-306&rft.issn=1365-7852&rft.eissn=1476-5608&rft_id=info:doi/10.1038/pcan.2010.18&rft_dat=%3Cgale_proqu%3EA242373977%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2645316390&rft_id=info:pmid/20567257&rft_galeid=A242373977&rfr_iscdi=true |